Bicara Therapeutics (BCAX) Accounts Payables (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Accounts Payables data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 57.14% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (up 57.14% YoY), and the FY2025 full-year result was $1.1 million, up 83.33% from the prior year.
• Accounts Payables for Q1 2026 stood at $1.1 million, roughly flat from $1.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $1.9 million in Q3 2025 and bottomed at $600000.0 in Q4 2024.
• The 4-year median for Accounts Payables is $1.1 million (2025), against an average of $1.1 million.
• The widest annual swing landed in 2024, when Accounts Payables slumped 40.0%; it then soared 83.33% in 2025.
• A 4-year view of Accounts Payables shows it stood at $1.0 million in 2023, then plunged by 40.0% to $600000.0 in 2024, then soared by 83.33% to $1.1 million in 2025, then changed by 0.0% to $1.1 million in 2026.
• The last three Accounts Payables figures came in at $1.1 million (Q1 2026), $1.1 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.

Peer Comparison